Literature DB >> 12481422

Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.

Mariko Kawakami1, Koji Kawakami, Raj K Puri.   

Abstract

Apoptosis is not only essential for homeostasis in normal cells but also in cancer cells, in which it is associated with cell death mechanisms caused by novel therapeutics. We have previously reported that interleukin-13 receptors (IL-13R) are constitutively overexpressed on a majority of human malignant glioma cell lines and primary cell cultures. In addition, we have reported that IL-13 cytotoxin, comprised of human IL-13 and a mutated form of Pseudomonas exotoxin, is highly and specifically cytotoxic to these cells and can lead to pronounced antitumor activity in malignant glioma tumors in animal models. However, the molecular mechanisms of tumor cytotoxicity induced by IL-13 cytotoxin are poorly understood. In this study, we demonstrate that glioma tumors undergo apoptotic cell death on intratumoral administration of IL-13 cytotoxin. This conclusion was made based on (a) time-dependent induction of several proapoptotic molecules, such as caspases (caspase-3, -8, and -9) in tumors; (b) cleavage of procaspase-3 and poly(ADP-ribose) polymerase (PARP); and (c) the release of cytochrome c from mitochondria to the cytosol on injection of IL-13 cytotoxin in U251 glioblastoma tumors established in immunodeficient animals. These indicators of two major pathways of apoptosis were detected in tumors even though IL-13 cytotoxin was no longer present in tumors. In addition, we found that inducible nitric oxide was expressed in tumors in a time-dependent manner with primary localization in infiltrating phagocytes after treatment with IL-13 cytotoxin. These studies demonstrate that IL-13 cytotoxin mediates apoptotic death of glioma cells, resulting in regression of established tumors. Our studies will help unravel the molecular pathways of cell death associated with tumor regression and provide additional insight and define apoptosis as possible surrogate marker of tumor response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481422

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

1.  Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Authors:  Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.

Authors:  Linda C Hsi; Suman Kundu; Juan Palomo; Bo Xu; Ryan Ficco; Michael A Vogelbaum; Martha K Cathcart
Journal:  Mol Cancer Ther       Date:  2011-05-19       Impact factor: 6.261

3.  Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

Authors:  Sandeep Kunwar; Susan Chang; Manfred Westphal; Michael Vogelbaum; John Sampson; Gene Barnett; Mark Shaffrey; Zvi Ram; Joseph Piepmeier; Michael Prados; David Croteau; Christoph Pedain; Pamela Leland; Syed R Husain; Bharat H Joshi; Raj K Puri
Journal:  Neuro Oncol       Date:  2010-02-04       Impact factor: 12.300

4.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Authors:  Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  J Neurooncol       Date:  2009-05-17       Impact factor: 4.130

5.  Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  Claudia Jakubzick; Esther S Choi; Kristin J Carpenter; Steven L Kunkel; Holly Evanoff; Fernando J Martinez; Kevin R Flaherty; Galen B Toews; Thomas V Colby; William D Travis; Bharat H Joshi; Raj K Puri; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

6.  Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.

Authors:  Irina V Balyasnikova; Derek A Wainwright; Elena Solomaha; Gina Lee; Yu Han; Bart Thaci; Maciej S Lesniak
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

7.  Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.

Authors:  Jing Han; Liming Yang; Raj K Puri
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.506

Review 8.  Advances in local therapy for glioblastoma - taking the fight to the tumour.

Authors:  Thomas S van Solinge; Lisa Nieland; E Antonio Chiocca; Marike L D Broekman
Journal:  Nat Rev Neurol       Date:  2022-03-11       Impact factor: 44.711

Review 9.  Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Authors:  Shaowei Zhu; Yuanyi Liu; Paul C Wang; Xinbin Gu; Liang Shan
Journal:  Biomed Res Int       Date:  2017-06-29       Impact factor: 3.411

Review 10.  Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors.

Authors:  Visish M Srinivasan; Chibawanye Ene; Brittany Parker Kerrigan; Frederick F Lang
Journal:  Neurosurg Clin N Am       Date:  2020-11-05       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.